
Dec 23 (Reuters) - Phio Pharmaceuticals Corp PHIO.O:
PHIO PHARMACEUTICALS CORP - TO BEGIN TOXICOLOGY STUDY FOR PH-762 BEFORE HUMAN TRIALS - SEC FILING
PHIO PHARMACEUTICALS CORP - NO DOSE-LIMITING TOXICITIES IN PH-762 TRIAL - SEC FILING
PHIO PHARMACEUTICALS CORP - INITIATIVES CONTINUING TO ADVANCE DELIVERY OF COMMERCIALLY VIABLE DRUG PRODUCT IN 2026
PHIO PHARMACEUTICALS CORP - PH-762 HAS BEEN WELL TOLERATED IN ALL ENROLLED PATIENTS IN EACH ESCALATING DOSE COHORT
Source text: [ID:n0001437749-25-038607]